Insights

  • Date

  • Content Type

  • Reset

Blog

Biopharma’s Big Inflection Point: There’s never been a better time to innovate with next-generation medicine

11.10.21

by Christian K. Schneider, MD

In all of the years I have been tracking and helping to drive...

White Paper

The Future of Advanced Therapies: Strategies to Evolve Global Health in a Post-COVID World

01.10.21
Driven by scientific innovations and impressive clinical outcomes, next-generation therapies are on the threshold of

Blog

How to create a smart integrated drug development plan including considerations for cell and gene therapies

29.06.21

by Diane Seimetz

An integrated drug development plan is a critical tool for the efficient and effective progression...

Blog

Risk Management Plans for ATMPs

13.06.21

by Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set...

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

01.06.21

by Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during...

Blog

Better late than never? What developers of SARS-CoV-2 vaccines in early-to -late-stage development should consider

12.05.21

by Michael Pfleiderer, Ilona Baraniak and Ciaran Greene

Unfortunately, as of today the ongoing pandemic is still far...